IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Novartis to Cut 1,960 Jobs in U.S.

8:12 AM MST | January 13, 2012 | Deepti Ramesh

Novartis (Basel, Switzerland) says it plans to restructure the company’s business in the U.S. The restructuring is mainly to respond to the loss of patent exclusivity for Diovan, the market-leading hypertension medication, expected in the U.S. in September 2012, and also because of the expected impact on worldwide sales of Rasilez/Tekturna after Altitude clinical study termination, the company says. The company will restructure its general medicines business in the U.S. market, and as a result, the field force will be reduced by about 1,630 positions and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa